BR112022017102A2 - Métodos para tratar esclerose múltipla progressiva primária (ppms), retardar a progressão de ppms, retardar o início de pelo menos um evento de progressão em um indivíduo com ppms, reduzir o risco de um indivíduo com ppms ter pelo menos um evento de progressão e reduzir a deficiência em um indivíduo com ppms e compostos - Google Patents

Métodos para tratar esclerose múltipla progressiva primária (ppms), retardar a progressão de ppms, retardar o início de pelo menos um evento de progressão em um indivíduo com ppms, reduzir o risco de um indivíduo com ppms ter pelo menos um evento de progressão e reduzir a deficiência em um indivíduo com ppms e compostos

Info

Publication number
BR112022017102A2
BR112022017102A2 BR112022017102A BR112022017102A BR112022017102A2 BR 112022017102 A2 BR112022017102 A2 BR 112022017102A2 BR 112022017102 A BR112022017102 A BR 112022017102A BR 112022017102 A BR112022017102 A BR 112022017102A BR 112022017102 A2 BR112022017102 A2 BR 112022017102A2
Authority
BR
Brazil
Prior art keywords
individual
progression
ppms
delay
reduce
Prior art date
Application number
BR112022017102A
Other languages
English (en)
Inventor
Garren Hideki
Huatung Teng Edmond
Viaccoz Aurelien
Von Buedingen Hans-Christian
Original Assignee
Genentech Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Hoffmann La Roche filed Critical Genentech Inc
Publication of BR112022017102A2 publication Critical patent/BR112022017102A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)

Abstract

MÉTODOS PARA TRATAR ESCLEROSE MÚLTIPLA PROGRESSIVA PRIMÁRIA (PPMS), RETARDAR A PROGRESSÃO DE PPMS, RETARDAR O INÍCIO DE PELO MENOS UM EVENTO DE PROGRESSÃO EM UM INDIVÍDUO COM PPMS, REDUZIR O RISCO DE UM INDIVÍDUO COM PPMS TER PELO MENOS UM EVENTO DE PROGRESSÃO E REDUZIR A DEFICIÊNCIA EM UM INDIVÍDUO COM PPMS E COMPOSTOS. São fornecidos neste documento métodos para tratar a Esclerose Múltipla Progressiva Primária (PPMS) em um indivíduo em necessidade dos mesmos, administrando ao indivíduo cerca de 200 mg de fenebrutinibe duas vezes ao dia, ou uma quantidade equivalente de um sal farmaceuticamente aceitável do mesmo.
BR112022017102A 2020-02-28 2021-02-25 Métodos para tratar esclerose múltipla progressiva primária (ppms), retardar a progressão de ppms, retardar o início de pelo menos um evento de progressão em um indivíduo com ppms, reduzir o risco de um indivíduo com ppms ter pelo menos um evento de progressão e reduzir a deficiência em um indivíduo com ppms e compostos BR112022017102A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062982872P 2020-02-28 2020-02-28
US202063051756P 2020-07-14 2020-07-14
PCT/US2021/019502 WO2021173740A1 (en) 2020-02-28 2021-02-25 Methods of treating primary progressive multiple sclerosis using an inhibitor of bruton's tyrosine kinase

Publications (1)

Publication Number Publication Date
BR112022017102A2 true BR112022017102A2 (pt) 2022-11-16

Family

ID=74885089

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022017102A BR112022017102A2 (pt) 2020-02-28 2021-02-25 Métodos para tratar esclerose múltipla progressiva primária (ppms), retardar a progressão de ppms, retardar o início de pelo menos um evento de progressão em um indivíduo com ppms, reduzir o risco de um indivíduo com ppms ter pelo menos um evento de progressão e reduzir a deficiência em um indivíduo com ppms e compostos

Country Status (13)

Country Link
US (1) US20230091561A1 (pt)
EP (1) EP4110339A1 (pt)
JP (1) JP2023515528A (pt)
KR (1) KR20220148826A (pt)
CN (1) CN115175682A (pt)
AU (1) AU2021227674A1 (pt)
BR (1) BR112022017102A2 (pt)
CA (1) CA3170685A1 (pt)
CL (1) CL2022002317A1 (pt)
IL (1) IL295476A (pt)
MX (1) MX2022010513A (pt)
TW (1) TW202146022A (pt)
WO (1) WO2021173740A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114028393B (zh) * 2021-11-07 2023-07-18 天津医科大学 阿帕替尼在制备治疗多发性硬化症药物的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
KR102451106B1 (ko) 2016-02-29 2022-10-06 에프. 호프만-라 로슈 아게 브루톤 티로신 키나제의 억제제를 포함하는 투여량 형태 조성물

Also Published As

Publication number Publication date
WO2021173740A1 (en) 2021-09-02
IL295476A (en) 2022-10-01
JP2023515528A (ja) 2023-04-13
EP4110339A1 (en) 2023-01-04
US20230091561A1 (en) 2023-03-23
CN115175682A (zh) 2022-10-11
MX2022010513A (es) 2022-09-21
KR20220148826A (ko) 2022-11-07
CL2022002317A1 (es) 2023-03-03
TW202146022A (zh) 2021-12-16
CA3170685A1 (en) 2021-09-02
AU2021227674A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
WO2020093006A8 (en) Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7)
EA202190630A1 (ru) Способы комбинированной терапии
ZA202109010B (en) Compounds and methods for the treatment of covid-19
BR112022004474A8 (pt) Método de tratamento ou prevenção de um câncer em um sujeito, molécula de ligação ao antígeno para uso neste e uso desta
BR112022011951A2 (pt) Tratamento de esclerose lateral amiotrófica e distúrbios relacionados
EA202090510A1 (ru) Способ лечения бокового амиотрофического склероза придопидином
BR112020016331A8 (pt) Métodos para tratar câncer com anticorpos anti-pd-1
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
BR112022022578A2 (pt) Novas composições e métodos de tratar doença covid-19
EA202190749A1 (ru) Способы комбинированной терапии
BR112022000231A2 (pt) Novos métodos
MX2023013508A (es) Inhibicion de la proteina de union a creb (cbp).
EP4279127A3 (en) Growth differentiation factor 15 as biomarker for metformin
BR112022026186A2 (pt) Combinação de um inibidor de bromodomínio cbp/p300 e um inibidor de kras
MX2022010258A (es) Composiciones y métodos para tratar la lesión renal.
BR112022017102A2 (pt) Métodos para tratar esclerose múltipla progressiva primária (ppms), retardar a progressão de ppms, retardar o início de pelo menos um evento de progressão em um indivíduo com ppms, reduzir o risco de um indivíduo com ppms ter pelo menos um evento de progressão e reduzir a deficiência em um indivíduo com ppms e compostos
EA202190776A1 (ru) Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами
BR112022025946A2 (pt) Composto, composição farmacêutica e método de tratamento de uma doença
MX2022012632A (es) Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington.
MX2022012310A (es) Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton.
BR112021010856A2 (pt) Vibegron para o tratamento de sintomas de bexiga hiperativa
BR112021024835A2 (pt) Tratamento para sinuclenopatias
WO2022240971A3 (en) Kras g12d inhibitors and uses thereof
BR112023002089A2 (pt) Compostos de piridazina 6-substituídos como degradadores de smarca2 e/ou smarca4
BR112022015800A2 (pt) Tratamento de colangite biliar primária com elafibranor